Grupo Sur

Clinical Research

BROCHURE



info@gruposur.ar

221 3144563

gruposur.ar

WHO WE ARE

Grupo Sur is an organization dedicated to generating knowledge to improve people's quality of life through clinical trials focused on the development of new methods for prevention, diagnosis and treatment.
We operate in conjunction with a network of clinical research sites unified under a single corporate entity to optimize, standardize, and accelerate clinical processes. We provide sponsors with pre-qualified sites of demonstrated reliability, offering centralized communication alongside the standardization of budgets and Clinical Trial Agreements (CTAs) to maximize operational efficiency.This model leverages a unified approach for multicenter studies, thereby facilitating expedited and high-quality data collection.

OUR HISTORY

Our team has been developing local, national and international Clinical Research protocols for over 25 years. Over the years we have conducted both intervention and observational studies of great contribution to scientific advances. Throughout our career we have positioned ourselves as the largest recruiters in Argentina and Latin America in different studies. The quality of our work has been validated by external quality audits by sponsors and inspections by the Argentine regulatory agency, the National Administration of Drugs, Foods and Medical Devices (ANMAT by its Spanish acronym). We also have ongoing monitoring, evaluation and oversight by the Clinical Research Ethics Committee (CEDIMP by its Spanish acronym), accredited by the Central Ethics Committee (CEC) of the Province of Buenos Aires, Argentina.
Since 2022, together with the College of Physicians, District I, La Plata, we've started a training program in Clinical Research for medical professionals.

ABOUT US


Efficiency
Quality
Framework
Inter Disciplinary
Experience
Confidence
Grupo Sur
Clinical Research

Framework

Since 2013, based in La Plata, Argentina, we manage a network of 6 clinical research centers dedicated to conducting clinical trials with scientific, ethical and operational excellence.

Quality and Confidence

Our work is supported by audits from international sponsors, satisfactory inspections from ANMAT, the implementation of standard operating procedures (SOPs) and a team trained under Good Clinical Practices (GCP).

Inter Disciplinary

Due to our interdisciplinary professional structure focused on data quality and patient well-being, we have established ourselves as a reliable and effective partner for sponsors, CROs, and healthcare institutions in the execution of clinical trials for the pharmaceutical industry.

Experience

- 25 years of experience
- 6.500 volunteers
- 140 completed clinical trials

  Phase 2: 40

  Phase 3: 100

  In 2025 we initiated the first phase 1B study, recruitment is ongoing.

  26 observational studies reporting our data to national and international entities
- Joint work with more than 40 sponsors & CROs
- Human resources: 60 people working
- Top enrollers at 70% of studies
- Over 30 scientific publications

Efficiency

Our structure ensures operational quality, technical expertise, and efficiency at every stage of a clinical trial.



ORGANIZATIONAL STRUCTURE

Grupo Sur Clinical Research

EXECUTIVE DIRECTORS

Ensures the alignment of the network with its values, mission and scientific objectives by providing strategic leadership, institutional decision-making, resource management and global supervision of the research system.

FINANCE DEPARTMENT

ADMINISTRATION AND FINANCE

Manages financial administration, reconciliation, and resource control. Ensures transparency, financial traceability, and compliance with accounting and tax obligations associated with research activities.

PURCHASING AND CONTRACTING

Manages contracts, budgets, and billing. Ensures transparency, financial traceability, and compliance with accounting.

HUMAN RESOURCES

Responsible for the recruitment, training, administration, and monitoring of staff. Ensures the appropriate assignment of roles, ongoing training (including GCP), performance reviews, and professional development of the team.

MEDICAL DEPARTMENT

ADMINISTRATION AND FACILITY MANAGEMENT

Coordinates subject´s visits, telephone follow-up and operational support for volunteers and professionals. Organizes transportation of subjects, availability of documentation and materials for each study.

PHARMACY AREA

Receiving, storing, preparing, and dispensing the investigational product under control and documentation standards. Managing cold chains, stock levels, returns, and destructions, while complying with applicable protocols and regulations to ensure full traceability throughout the entire circuit.

LABORATORY AREA

Collecting, processing, storing, preparing, and shipping biological samples according to the requirements of each protocol. Managing equipment, sample traceability, cold chains, and coordination with national and international central laboratories, in compliance with IATA regulations.

MEDICAL COORDINATION

Investigators and Sub-Investigators

Principal Investigators: Responsible for the strategic direction, ethical oversight, and compliance with the research protocol.

Sub-Investigators: Medical specialists in charge of clinical follow-up, diagnostic evaluation, and constant monitoring of patient safety.

IP/SI and Devices

Managing clinical documentation, electronic health records (EHR), digital research platforms (eCRF, IWRS, RealTime, ePRO), and associated medical devices. Ensuring data integrity, digital security, and technical support for investigators, coordinators, and patients.

Data

Data entry, query resolution, internal monitoring, and coordinated teamwork with CRAs. Ensuring the quality, integrity, and consistency of the information recorded in electronic data capture systems.

OPERATIONAL COORDINATION

Regulatory Affairs and Start-Up

Managing regulatory processes before IRBs/IECs, ANMAT, and institutional entities. Developing and managing submissions, amendments, contracts, approvals, and study start-up processes. Ensuring regulatory compliance and coordination between sponsors/CROs and participating sites.

Recruitment

Planning, executing, and evaluating participant recruitment strategies. Conducting preliminary screening, patient contact, targeted outreach, and collaboration across the network's sites to identify potential volunteers. Maintaining an active, constant, and updated referral network by medical specialty.



Institutional communication

Responsible for internal and external institutional communication, as well as the production of institutional visual communication materials. Managing community relations, digital outreach, social media management, and website oversight.

Quality

Responsible for standardizing, auditing, and continuously improving Grupo Sur's processes through SOP management, compliance monitoring, and the implementation of corrective actions.

ACADEMIC DEPARTMENT

Fellowship

Participating physicians receive: practical and theoretical training in clinical pharmacological research, as well as training in regulatory aspects and Good Clinical Practices (GCP).

Medical Research Course

With the support and recognition of the Medical Chamber (Distrito I La Plata), we develop the Clinical Research Training Course with the goal of training all those professionals who wish to join Clinical Research teams.

Scientific Publications

Responsible for guiding and promoting the publication of Grupo Sur's own research lines, focusing primarily on local epidemiological issues.



OUR TEAM

EXECUTIVE DIRECTORS

María Fernanda Alzogaray
Analía Mykietiuk

MEDICAL COORDINATION

María Victoria Vulcano
Mora Obed

Investigators and Sub-Investigators

Internal Medicine
Belén Alcorta
Liliana Montero Labat
Sergio Cuellar
Juliana Malacalza
Luciano Miguel Martínez

Infectious Diseases
Mora Obed
Sebastián Scala
María Daniela Tonin
Bettina Cooke
Esteban Nannini

Nephrology
María Elena Bruzzone

Pulmonology
Amparo Ivone Ritou
Federico Jauregui
Antonela Soledad Gatti
Daniel Orlando Luna Bautista

Oncology
Fabiana Marmissolle
Agustín González Sáenz
Mariana Sansano
Paola Edith Price

HIV and STDs
María Marta Greco

Pediatrics
María Victoria Vulcano
Maria Paula Lucarno
Viviana Mastri

Diabetology
Matías Re

Gastroenterology
Rocio Daiana Laurini

Gynecology
Melina Alzogaray
Juan Manuel Briones

Cardiology
Andrea Cecilia Longhi

OPERATIONAL COORDINATION

Agustín Romandetta




OUR NETWORK

Our network comprises adult and pediatric healthcare institutions located in La Plata,Pinamar and Córdoba, encompassing outpatient, inpatient, high-complexity, and surgical clinical profiles.

This network of centers allows for studies to be conducted across different specialties, geographic locations, age ranges, and levels of complexity.

The network operates under unified standards, with aligned procedures and consistent documentation, ensuring quality, reproducibility, and efficiency in every study.



CÓRDOBA

Site for adult population

Hospital Córdoba

LA PLATA

Sites for adult population

Instituto Médico Platense
Centro Médico Grupo Sur
Hospital Español
Nefroexcel

Site for pediatric population

Nueva Clínica del Niño

PINAMAR

Site for adult population

Clínica PINAMED

INSTITUTO MÉDICO PLATENSE

Country	Argentina
Province	Buenos Aires
City	La Plata
Address	51 #315
Web Page	www.gruposurinvestigacionclinica.com.ar @gruposur.ar
Point of Contact	Agustín Romandetta
Number of beds	76
Number of ICU beds	30
Number of nICU beds	17
Number of day care beds	8
Number of emergency room visits per month	2000
Number of outpatient offices	25
Laboratory	Certified by Fundación Bioquímica Argentina
Imaging Diagnosis	RX - CT scan - Nuclear medicine Ultrasound - Breast scan
Quality programs certifications	CENAS



CENTRO MÉDICO GRUPO SUR

Country	Argentina
Province	Buenos Aires
City	La Plata
Address	40 #482
Web Page	-
Point of Contact	Melina Alzogaray
Number of beds	N/A
Number of ICU beds	N/A
Number of nICU beds	N/A
Number of day care beds	1
Number of emergency room visits per month	N/A
Number of outpatient offices	9
Laboratory	Agreement with an external laboratory
Imaging Diagnosis	N/A
Quality programs certifications	-



HOSPITAL ESPAÑOL

Country	Argentina
Province	Buenos Aires
City	La Plata
Address	Calle 9 #175
Web Page/Social Media	www.hospitalespanol.org.ar
Point of Contact	María Marta Greco
Number of beds	81
Number of ICU beds	28
Number of nICU beds	16
Number of day care beds	10
Number of emergency room visits per month	4000
Number of outpatient offices	29
Laboratory	Accredited by Fundación Bioquímica Argentina
Imaging Diagnosis	RX - CT scan -Echocardiogram-Ultrasonography-MRI
Quality programs certifications	CENAS, CIDCAM



NEFROEXCEL

Country	Argentina
Province	Buenos Aires
City	La Plata
Address	51 #1111
Web Page/Social Media	-
Point of Contact	María Elena Bruzzone
Number of beds	N/A
Number of ICU beds	N/A
Number of nICU beds	N/A
Number of day care beds	15
Number of emergency room visits per month	N/A
Number of outpatient offices	2
Laboratory	Agreement with external laboratory
Imaging Diagnosis	N/A
Quality programs certifications	-



PINAMED

Country	Argentina
Province	Buenos Aires
City	Pinamar
Address	Rivadavia #1083
Web Page/Social Media	@clinicapinamed
Point of Contact	Iván Battistessa
Number of beds	N/A
Number of ICU beds	N/A
Number of nICU beds	N/A
Number of day care beds	4
Number of emergency room visits per month	
Number of outpatient offices	19
Laboratory	Yes
Imaging Diagnosis	RX-CT scan-Echocardiogram-Ultrasonography-Breast scan
Quality programs certifications	-



HOSPITAL DE CÓRDOBA

Country	Argentina
Province	Córdoba
City	Córdoba
Address	Av Patria #656
Web Page/Social Media	-
Point of Contact	Aldana Mano
Number of beds	145
Number of ICU beds	38
Number of nICU beds	N/A
Number of day care beds	N/A
Number of emergency room visits per month	6000
Number of outpatient offices	45
Laboratory	PEEC certification provided by Fundación Bioquímica Argentina
Imaging Diagnosis	RX - CT scan -MRI
Quality programs certifications	-



CONDUCTED STUDIES
(RECENT YEARS)

Study	Description
AC 061 A 302	A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) / 2014
FLU002 Plus New	An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses / 2014-2015
FLU003	An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses 2014-2015
T705Aus317	A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza
Revive-2	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)
NAB-BC-3781-3101	A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia/ 2016
MK-7655A-014	A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia / 2016-2019
FLU-IVIG	Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG) / 2017-2018
NAB-BC-3781-3102	A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia / 2017
NOPRODRSV0006	Study of adults hospitalized with ARI during the influenza/RSV 2017-1019
64041575RSV2003	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus
Theravance 0112	A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including infective endocarditis / 2017
ML-3341-306	A phase 3, multicenter, randomized, double-blind, comparator-controlled study to evaluate the safety and efficacy of intravenous to oral Delafloxacin in adult subjects with community-acquired Bacterial Pneumonia / 2017 - 2018

Study	Description
63623872FLZ3001	A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection / 2018 -2020
63623872FLZ3002	A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection who Are at Risk of Developing Complications / 2018-2020
Ri-CoDIFy 1 S	A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI) / 2020
ENSEMBLE	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older / 2020 -2024
CT-INM005-01	Phase 2/3, adaptive, randomized, controlled, double-blind study to study the pharmacokinetics, efficacy and safety of hyperimmune equine serum (INM005) in adult patients with confirmed moderate-severe SARS-CoV2 disease. 2020
CS-CTP-AD5NCOV-III	A global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase III clinical trial to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above / 2020-2022
(ACTIV-1 IM	Immune Modulators for Treating COVID-19 /2021-2022
C3671013	A phase 3 study to evaluate the efficacy, immunogenicity, and Safety of respiratory syncytial virus (RSV) prefusion f subunit Vaccine in adults / 2022-2024
ARVAC - F2/3 – 002	Phase 2/3 study to evaluate the safety, tolerability and immunogenicity of a recombinant protein vaccine against SARS-CoV-2 (ARVAC Cecilia Grierson), in a population of adult volunteers previously vaccinated against the SARS-CoV-2 virus
TILIA_D9185C00001	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). 2022 - ongoing
EDP 938-104	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications
DEBIO: 1450-BJI-205	Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus
DOMPE REP0321	Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled,parallel-group phase III trial. (REPAVID-22). 2023 – Finished
MICU MRXC-302	A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections. 2023- Finished
Bordetella	Frequency of Bordetella Pertussis infection in older adults who present cough in different cities of Argentina / 2022 - 2024
eVOLVE-Lung02	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemothe rapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02) / 2024 - ongoing.

Study	Description
BaxDuo ARTIC D6972C00003	A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure/ 2024 - Finished
INSIGHT 018/STRIVE	A multicenter, adaptive, randomized, controlled trial platform to evaluate safety and efficacy of strategies and treatments for hospitalized patients with respiratory infections. / 2024 Finished
AJAX D8210C00003	Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA - AJAX Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA - AJAX / 2024 - Finished
INSIGHT 012 /OTAC	An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 / 2024 - ongoing
SPERO/SPR994-305:	A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously administered imipenem- cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) / 2024 - Finished
D6972C00002 BaxDuo Pacific	A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure.2025 Ongoing
D9181C00002 UMBRIEL	A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids. 2026 Ongoing
GSK 222730	A Phase IB clinical study to evaluate the safety, tolerability, pharmacology, and clinical activity of injectable GSK5733584 in subjects with advanced solid tumors. Start date: July 30, 2025 – ongoing
ITU / GSK 219685	An uninterrupted, phase 1/2, observer-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of a UTI vaccine when administered to adults aged 18 to 64 years, inclusive, and its clinical efficacy when administered to women aged 18 to 64 years, inclusive Start date:: septembre 26 -ongoing
D5241C00007	A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY). Start day: November 18 2025 - Ongoing
INSIGHT - STRIVE 002	International Observational Study of Adults with Acute Infection – STRIVE Network (Strategies and Treatments for Respiratory Infections and Viral Emergencies). Start day: January 28, 2026 - Ongoing
C4771002_BEETHOVEN	A phase 3, placebo-controlled, double-blinded, randomized study to evaluate the efficacy, safety, and tolerability of a clostridioides difficile vaccine in adults 50 years of age and older. Start day: may 2026 - Ongoing.
C5091017	A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With Coronavirus Disease 2019 (COVID-19) Who Are Not Hospitalized But Are at Risk For Severe Disease. 2026
KAI-9531-3103 KAINETIC-1	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes. 2026

Estudio	Descripción
K9531-3104	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes. 2026
D9440C00004 SERENIA	A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA). Start day: June 2026

“ ”